Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer
Launched by BARBARA ANN KARMANOS CANCER INSTITUTE · Jun 9, 2004
Trial Information
Current as of March 16, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES: I. Evaluate the antitumor activity of pyrazoloacridine (PZA) administered by 3-hour infusion to patients with advanced non small cell lung cancer (NSCLC). II. Determine the qualitative and quantitative toxicities of PZA administered on this schedule. III. Determine the response and survival durations of NSCLC patients treated with PZA.
OUTLINE: Single-Agent Chemotherapy. Pyrazoloacridine, PZA, NSC-366140.
PROJECTED ACCRUAL: If 2 or 3 responses are observed in the first 18 evaluable patients, 12 additional patients will be entered. Accrual is expected to take 5-12 months.
Gender
ALL
Eligibility criteria
- • DISEASE CHARACTERISTICS: Histologically confirmed non small cell lung cancer ineligible for higher priority protocols Sputum cytology acceptable Stage IIIB/IV Must have measurable or evaluable disease Lesion outside prior radiotherapy fields Cytology-positive pleural effusion and ascites are neither measurable nor evaluable No brain metastases on CT
- • PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Zubrod 0-2 Life expectancy: At least 12 weeks Hematopoietic: Absolute granulocyte count greater than 2,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL Renal: Creatinine less than 1.5 mg/dL Other: No pregnant or nursing women Negative pregnancy test required of fertile women Effective contraception required of fertile patients Blood/body fluid analyses within 7 days prior to registration Imaging/exams for tumor measurement within 28 days prior to registration
- • PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: One prior adjuvant or neoadjuvant chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since radiotherapy and recovered AND Progressive disease outside of radiation port Surgery: Recovered from any prior surgery
Trial Officials
Antoinette J. Wozniak, MD
Study Chair
Barbara Ann Karmanos Cancer Institute
About Barbara Ann Karmanos Cancer Institute
The Barbara Ann Karmanos Cancer Institute, a leading nonprofit cancer research and treatment center located in Detroit, Michigan, is dedicated to advancing innovative cancer therapies and improving patient outcomes through rigorous clinical trials. Affiliated with Wayne State University, the institute emphasizes a multidisciplinary approach, integrating cutting-edge research with compassionate patient care. With a commitment to translating laboratory discoveries into effective treatments, Karmanos plays a pivotal role in the national landscape of cancer research, focusing on personalized medicine and the development of novel therapeutic strategies to combat various forms of cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Detroit, Michigan, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials